Navigation Links
Fuisz Pharma Releases Clinical Photos of Its Opioid Abuse Detection System
Date:12/6/2010

MIAMI, Dec. 6, 2010 /PRNewswire-USNewswire/ -- Fuisz Pharma today released photos of what the clinician will see in a standard nasal otoscopic exam in the case of a patient abusing an opioid, like Oxycontin® and others, through snorting. A food safe dye included in the tablet creates easily visible, long lasting but temporary nasal stain.  Crushing and snorting opioids is the most common method of opioid abuse. The photos are taken at 12 hours, 24 hours and 48 hours after snorting. These photos include attempts to defeat the system – which prove futile – by attempting to clean the nose through nasal lavage. The importance of these photos is to demonstrate for the first time an objective criterion for caregivers, emergency personnel and law enforcement personnel to detect opioid abuse. Presently the REMS that are mandated by the FDA do not have any objective criteria wherein the Caregiver and others have the ability to detect abuse. The nasal staining demonstrated by these clinical pictures is not the only detection feature of the Fuisz Closed Loop Diagnostic system.  Other methods include the staining the of the oral mucosa where a tablet is crushed and diverted for buccal or sublingual use (instead of the directed swallowing), as well as a method of urine detection that does not require chemistries. These methods are covered by pending patents and issued patent claims (US 7,214,385 "Pharmaceutical Formulation Containing Dye") that are owned by Fuisz Pharma.

(Photo: http://photos.prnewswire.com/prnh/20101206/DC11307-a)

(Photo: http://photos.prnewswire.com/prnh/20101206/DC11307-b)

(Photo: http://photos.prnewswire.com/prnh/20101206/DC11307-c)

Joseph Fuisz, Managing Member for Fuisz Pharma, commented:  "The FDA trend in the abuse deterrence category is to require the disclosure of individual features that relate to deterring abuse.  The consequence of such labeling is that the products that will ultimately dominate this category will be those products that combine multiple deterrence features.   Importantly, other abuse deterrence methods – like the use of antagonists, antagonist sequestration, crush resistant tablet formulations, etc. – do not have clear patent protection and thus are susceptible to generic competition.  In contrast, our highly effective dye methods have dominant, issued patent claims affording them excellent patent protection."

Mr. Fuisz continued, "Because the Fuisz detection features employ inactive, food safe materials, these features can be added to existing drug approvals, including NDAs and ANDAs, as post approval supplements.   This simplified regulatory procedure offers a compelling route to enable companies to add detection features to existing products."

Fuisz Pharma is a private pharmaceutical technology company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma.  The Fuiszes were recently issued a patent covering the programming of personal analyzers for analyte and clucose levels (US 7,824,612 "Bodily fluid analyzer, and system including same and method for programming same"). Fuisz Pharma has its headquarters in Miami. www.fuisz.com


'/>"/>
SOURCE Fuisz Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fuisz Announces Issuance of Patent for the New Generation of Glucose and Other Analyte Analyzers
2. Fuisz Pharma Announces Acquisition of Key Anti Opiate Abuse Patent to Complement its Anti Opiate Abuse Platform
3. FUISZ Announces Advances in Devices and Solid Dosage Form
4. Fuisz Pharma Announces Novel Anti Abuse System for Opiates
5. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
6. Caraco Receives Sun Pharma Proposal to Purchase All Outstanding Shares
7. Purdue Pharma L.P. Re-launches Partners Against Pain Website
8. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
9. Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
10. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
11. Access Pharmaceuticals Updates MuGard Website With First Patient Testimonial Video
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Calif. , Feb. 12, 2016  Sequent Medical, ... in a study to evaluate the safety and effectiveness ... the treatment of ruptured intracranial aneurysms.  Prof Laurent ... Hospital, in Paris, France and ... patient. France and Germany.  ...
(Date:2/12/2016)... 2016  OMS Supply, a large provider of oral ... today the recent launching of their new company website. ... features that enhance the user experience and enable practitioners ... --> --> Despite the ... that started in early 2016, they have already made ...
(Date:2/11/2016)... - Cardiac Marker Diagnostic ... and Cancer Therapy. - European Point of Care ... - Key Diagnostic Testing Markets. - Molecular ... Genetic Testing. - Molecular Diagnostics in Infectious Disease ... Diagnostic Products World Markets. - Point of Care ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... ... Vail knee specialist Robert LaPrade, MD, PhD was named one ... consists of physicians establishing, leading and partnering with ambulatory surgery centers across the United ... Center, also known as an ASC, is a modern health care facility focused on ...
(Date:2/12/2016)... ... 12, 2016 , ... Donor Network West, the organ procurement organization that heals ... with San Ramon Regional Medical Center. Under the collaboration, the first of its kind, ... accommodate a more certain time frame for donor families for the recovery of organs. ...
(Date:2/12/2016)... TX (PRWEB) , ... February 12, 2016 , ... ... of southwest Houston and surrounding communities by continuing it’s commitment to act as ... Family Promise. The organization works closely with area homeless families to fulfill immediate ...
(Date:2/12/2016)... ... 12, 2016 , ... Atlantic Information Services, Inc. (AIS) is ... an upcoming Feb. 24 webinar that will discuss ways health plans and PBMs ... as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost PCSK9 inhibitors to treat ...
(Date:2/12/2016)... Ranch, Colo. (PRWEB) , ... February 12, 2016 , ... ... over the past 35 years. A president has access to health and wellness resources ... of the free world, no single individual has a schedule as frenetic as the ...
Breaking Medicine News(10 mins):